Literature DB >> 27254258

Buspirone reduces sexual risk-taking intent but not cocaine self-administration.

B Levi Bolin1, Joshua A Lile1, Katherine R Marks2, Joshua S Beckmann2, Craig R Rush1, William W Stoops1.   

Abstract

Impulsive sexual decision-making may underlie sexual risk-taking behavior that contributes to the disproportionately high prevalence of HIV infection among cocaine users. Delay-discounting procedures measure impulsive decision-making and may provide insight into the underlying mechanisms of sexual risk-taking behavior. The anxiolytic drug buspirone reduces delay discounting in rats and blunts the reinforcing effects of cocaine in some preclinical studies suggesting that it might have utility in the treatment of cocaine-use disorders. This study determined whether buspirone mitigates impulsive risky sexual decision-making in cocaine users on a sexual delay-discounting procedure. The effects of buspirone maintenance on the abuse-related and physiological effects of cocaine were also tested. Nine (N = 9) current cocaine users completed a repeated-measures, inpatient protocol in which sexual delay discounting was assessed after 3 days of maintenance on placebo and buspirone (30 mg/day) in counterbalanced order. The reinforcing, subject-rated, and physiological effects of placebo and intranasal cocaine (15 and 45 mg) were also assessed during buspirone and placebo maintenance. Buspirone increased the likelihood of condom use for hypothetical sexual partners that were categorized as most likely to have a sexually transmitted infection and least sexually desirable. Cocaine functioned as a reinforcer and increased positive subjective effects ratings, but buspirone maintenance did not impact these effects of cocaine. Buspirone was also safe and tolerable when combined with cocaine and may have blunted some its cardiovascular effects. The results from the sexual delay-discounting procedure indicate that buspirone may reduce preference for riskier sex in cocaine users. (PsycINFO Database Record (c) 2016 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27254258      PMCID: PMC4896094          DOI: 10.1037/pha0000076

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  56 in total

Review 1.  Role of D1 and D2 dopamine receptors in the behavioral effects of cocaine.

Authors:  R D Spealman; J Bergman; B K Madras; J B Kamien; K F Melia
Journal:  Neurochem Int       Date:  1992-03       Impact factor: 3.921

2.  Differences in self-reported and behavioral measures of impulsivity in recreational and dependent cocaine users.

Authors:  Matthias Vonmoos; Lea M Hulka; Katrin H Preller; Daniela Jenni; Claudia Schulz; Markus R Baumgartner; Boris B Quednow
Journal:  Drug Alcohol Depend       Date:  2013-06-24       Impact factor: 4.492

3.  Polydrug abusers display impaired discrimination-reversal learning in a model of behavioural control.

Authors:  Mark T Fillmore; Craig R Rush
Journal:  J Psychopharmacol       Date:  2005-09-20       Impact factor: 4.153

Review 4.  A review of delay-discounting research with humans: relations to drug use and gambling.

Authors:  Brady Reynolds
Journal:  Behav Pharmacol       Date:  2006-12       Impact factor: 2.293

5.  Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Authors:  Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

6.  Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans.

Authors:  Craig R Rush; William W Stoops; Lon R Hays; Paul E A Glaser; Lon S Hays
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

7.  Non-injection and injection drug use and STI/HIV risk in the United States: the degree to which sexual risk behaviors versus sex with an STI-infected partner account for infection transmission among drug users.

Authors:  Maria R Khan; Amanda Berger; Jordana Hemberg; Allison O'Neill; Typhanye Penniman Dyer; Kristina Smyrk
Journal:  AIDS Behav       Date:  2013-03

Review 8.  Anxiety and substance use disorders: co-occurrence and clinical issues.

Authors:  Florence Vorspan; Wajdi Mehtelli; Gaël Dupuy; Vanessa Bloch; Jean-Pierre Lépine
Journal:  Curr Psychiatry Rep       Date:  2015-02       Impact factor: 5.285

Review 9.  Dopamine D3 receptor ligands for drug addiction treatment: update on recent findings.

Authors:  Bernard Le Foll; Ginetta Collo; Eugenii A Rabiner; Isabelle Boileau; Emilio Merlo Pich; Pierre Sokoloff
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

10.  Modafinil, but not escitalopram, improves working memory and sustained attention in long-term, high-dose cocaine users.

Authors:  A D Kalechstein; J J Mahoney; J H Yoon; R Bennett; R De la Garza
Journal:  Neuropharmacology       Date:  2012-07-13       Impact factor: 5.250

View more
  13 in total

Review 1.  Unpredictability as a modulator of drug self-administration: Relevance for substance-use disorders.

Authors:  Sally L Huskinson
Journal:  Behav Processes       Date:  2020-06-08       Impact factor: 1.777

2.  Effects of lorcaserin and buspirone, administered alone and as a mixture, on cocaine self-administration in male and female rhesus monkeys.

Authors:  Gregory T Collins; Charles P France
Journal:  Exp Clin Psychopharmacol       Date:  2018-06-28       Impact factor: 3.157

Review 3.  Pharmacotherapies for decreasing maladaptive choice in drug addiction: Targeting the behavior and the drug.

Authors:  Frank N Perkins; Kevin B Freeman
Journal:  Pharmacol Biochem Behav       Date:  2017-06-27       Impact factor: 3.533

Review 4.  Does being drunk or high cause HIV sexual risk behavior? A systematic review of drug administration studies.

Authors:  Meredith S Berry; Matthew W Johnson
Journal:  Pharmacol Biochem Behav       Date:  2017-08-24       Impact factor: 3.533

Review 5.  Utility of Nonhuman Primates in Substance Use Disorders Research.

Authors:  Matthew L Banks; Paul W Czoty; Sidney S Negus
Journal:  ILAR J       Date:  2017-12-01

6.  Effects of Acute and Chronic Treatments with Dopamine D2 and D3 Receptor Ligands on Cocaine versus Food Choice in Rats.

Authors:  Morgane Thomsen; Andrew C Barrett; Paul Butler; S Stevens Negus; S Barak Caine
Journal:  J Pharmacol Exp Ther       Date:  2017-05-04       Impact factor: 4.030

7.  Demographic and sexual risk predictors of delay discounting of condom-protected sex.

Authors:  Mary M Sweeney; Meredith S Berry; Patrick S Johnson; Evan S Herrmann; Steven E Meredith; Matthew W Johnson
Journal:  Psychol Health       Date:  2019-07-16

Review 8.  Insights from Preclinical Choice Models on Treating Drug Addiction.

Authors:  Matthew L Banks; S Stevens Negus
Journal:  Trends Pharmacol Sci       Date:  2016-12-02       Impact factor: 14.819

Review 9.  Immunopharmacotherapies for Treating Opioid Use Disorder.

Authors:  Matthew L Banks; Margaret E Olson; Kim D Janda
Journal:  Trends Pharmacol Sci       Date:  2018-11       Impact factor: 14.819

10.  Buspirone maintenance does not alter the reinforcing, subjective, and cardiovascular effects of intranasal methamphetamine.

Authors:  Anna R Reynolds; Justin C Strickland; William W Stoops; Joshua A Lile; Craig R Rush
Journal:  Drug Alcohol Depend       Date:  2017-09-22       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.